Everything below concerns regulatory status. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
=== Hydrogen isotope formation === 1H, with one proton and no neutrons, is the most abundant nuclide in the Solar System, formed in the earliest rounds of stellar explosions after the Big Bang. After the universe exploded into life, the hot and dense cloud of particles began to cool, first forming subatomic particles like quarks and electrons, which then condensed to form protons and neutrons. Elements larger than hydrogen and helium were produced with successive stars, forming from the energy released during supernovae. Deuterium, 2H, with one proton and one neutron, is also known to have cosmic origin. Like protium, deuterium was produced very early in the universe's history, during Big Bang nucleosynthesis (BBN). As protons and neutrons combined, helium-4 was produced with a deuterium intermediate. Alpha reactions with 4He produce many of the larger elements that dominate today's Solar System. However, before the universe cooled, high-energy photons destroyed any deuterium, preventing larger element formation. This is called the deuterium bottleneck, a restriction on the timeline for nucleosynthesis. All of today's deuterium originated from this proton-proton fusion after enough cooling. Tritium, 3H, with one proton and two neutrons, was produced by proton and neutron collisions in the early universe as well, but it has since radioactively decayed to helium-3. Today's tritium cannot be from BBN, due to tritium's short half-life, 12.3 years. Today's 3H concentration is instead governed by nuclear reactions and cosmic rays.
While roughly 400 public buildings in Ontario contain RAAC, the Science Centre is currently the only one in the province closed due to these concerns. The Ford government expedited its plan to relocate the Science Centre to the waterfront, targeting a 2028 opening, with a temporary location slated for January 2026. This drew further criticism, including from Moriyama Teshima Architects, the firm founded by the Science Centre's original architect. The architects offered to do pro bono design consulting services for the Government of Ontario to support immediate repairs to the roof, and called for other organizations to join the effort to facilitate repairs. Private donors, including Geoffrey Hinton, offered up to $1 million to fund repairs for the existing facility, but the province did not respond to these offers. By October 31, 2024, most of the exhibits had been moved to storage facilities in northern Toronto and Guelph, while the animals and plants had been transferred to the Toronto Zoo and The Village at Black Creek. Temporary pop-up exhibits have since opened at Sherway Gardens and Toronto's Harbourfront Centre.
== History == Vacutainer technology was developed in 1947 by Joseph Kleiner, and is currently marketed by Becton Dickinson (B-D). The Vacutainer was preceded by other vacuum-based phlebotomy technology such as the Keidel vacuum. The plastic tube version, known as Vacutainer PLUS, was developed at B-D in the early 1990s by E. Vogler, D. Montgomery and G. Harper amongst others of the Surface Science Group as US patents 5344611, 5326535, 5320812, 5257633 and 5246666. Vacutainers are widely used in phlebotomy in developed countries due to safety and ease of use. Vacutainers have the advantage of being prepared with additives, allowing easy multi-tube draws, and having a lower chance of hemolysis. In developing countries, it is still common to draw blood using a syringe or syringes. Many brands have now started manufacturing Vaccutainer such as Vacu-8, Hemo Tube and Hemo Vac Plus. These tubes are now also available in pre-barcoded forms.
== Increasing stability of peptide drugs == Many strategies have been employed to increase the stability of peptide drugs, because although they have so many desirable characteristics, they are short lived in the body as a result of rapid degradation and clearance. With half-lives of some peptides and proteins only being a few minutes, they are very ineffective in drug delivery. Mechanisms involved in their clearance include peripheral blood mediated elimination by proteolysis, renal and hepatic elimination, and also receptor-mediated endocytosis. One of the main reasons for such rapid clearance is molecular weight. Molecules that have a low molecular weight (40-50 kDa) are rapidly cleared by renal filtration via the glomerular filtration barrier (GBM) into the urine. As a result of this, increasing the size of a peptide drug is a good starting point to improve half-life. Peptide modifications to extend half-life include PEGylation, glycosylation, cyclization, serum albumin binding, and lipidation. PEGylation is the attachment of polyethylene glycol (PEG) chains to the peptide via covalent bonds, helping to increase molecular weight, and limit enzymatic degradation as a result of steric hindrance caused by adding the PEG. PEGylation offers a number of benefits for pharmaceutical applications such as improved water solubility, high mobility in solution, as well as low toxicity and low immunogenicity. This does however depend on the molecular weight of the attached PEG.
Sources: en.wikipedia.org
== Function == The basic function, as already mentioned (see: Translocase § Definition), is to "catalyse the movement of ions or molecules across membranes or their separation within membranes". This form of membrane transport is classified under active membrane transport, an energy-requiring process of pumping molecules and ions across membranes against a concentration gradient. Translocases biological importance relies primarily on their critical function, in the way that they provide movement across the cell's membrane in many cellular processes that are substantial, such as:
cutting the civil list abolishing some unnecessary court expenses reducing ministers' salaries recalling former Murattian officers into the army reorganizing the army The new ruler, however, did not accept political and institutional reforms demandede by the liberals. Instead he propped up the police regime established by his predecessors and crushed any hint of revolt. However, unlike his forbears, Ferdinand II was aware of conditions in the outlying provinces and made official trips to visit them. The first came on 7 April 1833, when the king visited Calabria and surroundings, returning to the capital on May 6. During his visit he granted pardons, decreed bridges and roads, corrected arbitrary actions of public administrators and bestowed substantial relief to earthquake victims of the 8 March 1832 earthquake that damaged the Crati and Coraci basin. Before the outbreak of the revolutions of 1848, Calabria was the scene of uprisings, all of which were suppressed. The protagonists were from other parts of Italy, such as the Venetian Bandiera brothers, who arrived in 1844 to lend support to the Cosenza revolt. They were betrayed by one of their comrades, captured by the gendarmerie, and executed in August after a summary trial. Calabrians such as the Five Martyrs of Gerace (Michele Bello, Pietro Mazzoni, Gaetano Ruffo, Domenico Salvadori and Rocco Verduci) in 1847 tried to make the Gerace district rise up as part of the Mazzinian uprising in Reggio Calabria and Messina on 2 September 1847, were shot after the suppression of the uprising.
A NATO spokesperson said, "discussions among NATO allies on the framework [Trump] referenced will focus on ensuring Arctic security through the collective efforts of allies, especially the seven Arctic allies". Greenland prime minister Jens-Frederik Nielsen emphasised that "nobody else than Greenland and the Kingdom of Denmark have the mandate to make deals or agreements about Greenland and the Kingdom of Denmark". Trump's comments in Davos were described as a great climbdown. Reuters reported that his reversal of policy followed pressure by his own aides opposing an invasion of Greenland. Former American NATO ambassador R. Nicholas Burns said Trump had clearly backed down in the face of tough military, economic, and political resistance from the Europeans that the Trump administration had not calculated. Trump's behaviour during 2025 and 2026 was described as having damaged the United States standing in the world and how allies see the nation in the long term, while resulting in no other outcome than maintaining Greenland's status quo. CNN reported that no actual document exists yet and that the information available indicates that the supposed deal "sounds a lot like what the United States already had", and described the affair as "one of the most erratic episodes involving a modern president on the world stage". Greenlandic politician Tillie Martinussen said: "We can never really trust America again." Trump's reversal was widely referred to as a TACO moment. The New York Times argued that it showed the "limits of his coercive powers".
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.